Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation.
Epidemiological and in vivo and in vitro experimental studies have suggested that fermented milks may interfere with the emergence and/or the development of colon cancer. The results, however, remain inconclusive. This prompted us to develop a new approach based on the use of HT-29, a cultured human colon cancer cell line, to study at the cellular level the effect of fermented milks on colon cancer cell growth and differentiation characteristics. Undifferentiated HT-29 cells have been grown in the continuous presence of milks fermented by one of the following bacterial populations: Lactobacillus helveticus, Bifidobacterium, L.acidophilus or a mix of Streptococcus thermophilus and L. bulgaricus. Penicillin G was added to the cell culture medium, resulting in a complete blockade of bacterial growth without significant effect on bacterial viability. One out of the four bacteria species studied, namely L.acidophilus, was without effect on both cell growth and differentiation. The three other bacterial strains induced a significant, although variable, reduction in the growth rate of HT-29 cells, which resulted in a 10-50% decrease in the cell number at steady-state (i.e. at cell confluency). The most efficient strains in lowering the HT-29 growth rate were L. helveticus and Bifidobacterium. Concomitantly, the specific activities of dipeptidyl peptidase IV (DPP IV), a sensitive and specific marker of HT-29 cell differentiation, and that of three other brush border enzymes (sucrase, aminopeptidase N and alkaline phosphatase) were significantly increased, thus suggesting that these cells may have entered a differentiation process. Altogether, these results indicate that the use of cultured colon cancer cells may be a useful tool to further study the effect of fermented milks on colon cancer and that bacterial strains may exert a different and specific effect on cancer cell growth and differentiation when used in fermented milk products.
INSERM, U239, CHU X Bichat, Paris, France.
L
L
Baricault
G
G
Denariaz
J J
JJ
Houri
C
C
Bouley
C
C
Sapin
G
G
Trugnan
D000818:Animals; D001644:Bifidobacterium / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000201:enzymology / Q000473:pathology* / Q000517:prevention & control*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D005285:Fermentation; D006801:Humans; D007778:Lactobacillus / Q000378:metabolism; D008892:Milk / Q000737:chemistry / Q000382:microbiology / Q000502:physiology; D008894:Milk Proteins / Q000494:pharmacology; D012680:Sensitivity and Specificity; D013291:Streptococcus / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects
D008894:Milk Proteins; D018819:Dipeptidyl Peptidase 4